nal-IRI /Experimental

Phase 2Small molecule

NNational Health Research Institutes, Taiwan

nal-IRI /Experimental is one of 42 small molecule programs targeting Gastric Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastric CancerRecruiting

Gastric CancerPhase 2

Recruiting

Competition

Competitive Landscape

181 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

24 2

Camptosar

Pfizer

Phase 3

23 3

Keytruda

Merck & Co.

Phase 3

20 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

55 5

Taxotere

AAvyxa

Phase 3

45 6

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

90 7

Avastin

Roche

Phase 3

11 8

Abraxane

Bristol-Myers Squibb

Phase 3

11 9

Cyramza

Eli Lilly

Phase 3

10 10

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Gastric Cancer

NCT05927857

Clinical

Trials by Indication[1]

Gastric Cancer1 trial

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

Recruiting·NNational Health Research Institutes, Taiwan·Phase 1/2·NCT05927857·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for nal-IRI /Experimental. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — nal-IRI /Experimental compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for nal-IRI /Experimental. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Health Research Institutes, Taiwan company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Health Research Institutes, Taiwan

nal-IRI /Experimental

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Gastric Cancer1 trial

References

Drug Info

Quick Facts

Related News